| Medical and Health Sciences | 2021-2025 | 218 | IT 19 | 99.96 |
| Biological Sciences | 2021-2025 | 295 | IT 6 | 99.70 |
| Infectious Diseases | Lifetime | 49 | IT 1 | 99.82 |
| Applied Microbiology and Biotechnology | Lifetime | 3 | IT 1 | 99.69 |
| Epidemiology | Lifetime | 337 | IT 13 | 99.59 |
| Molecular Medicine | Lifetime | 18 | IT 2 | 99.60 |
| Clinical Pharmacology | Lifetime | 184 | IT 7 | 99.24 |
| Clinical Biochemistry | Lifetime | 182 | IT 7 | 96.80 |
| Critical Care and Intensive Care Medicine | Lifetime | 262 | IT 12 | 94.74 |
| Infectious Diseases | 2021-2025 | 9 | IT 1 | 99.84 |
| Epidemiology | 2021-2025 | 42 | IT 5 | 99.78 |
| Molecular Medicine | 2021-2025 | 2 | IT 1 | 99.56 |
| Applied Microbiology and Biotechnology | 2021-2025 | 4 | IT 1 | 98.57 |
| Clinical Pharmacology | 2021-2025 | 122 | IT 6 | 95.75 |
| Clinical Biochemistry | 2021-2025 | 30 | IT 3 | 92.10 |
| Antibiotic Use and Resistance | Lifetime | 5 | IT 1 | 99.94 |
| Antibiotics Pharmacokinetics and Efficacy | Lifetime | 11 | IT 1 | 99.91 |
| Antibiotic Resistance in Bacteria | Lifetime | 16 | IT 1 | 99.91 |
| Bacterial Identification and Susceptibility Testing | Lifetime | 22 | IT 1 | 99.78 |
| Antifungal resistance and susceptibility | Lifetime | 36 | IT 4 | 99.75 |
| Pneumonia and Respiratory Infections | Lifetime | 71 | IT 4 | 99.63 |
| Antimicrobial Resistance in Staphylococcus | Lifetime | 61 | IT 1 | 99.60 |
| Nosocomial Infections in ICU | Lifetime | 27 | IT 1 | 99.67 |
| Fungal Infections and Studies | Lifetime | 83 | IT 5 | 99.37 |
| COVID-19 Clinical Research Studies | Lifetime | 345 | IT 40 | 98.52 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 182 | IT 9 | 98.84 |
| Streptococcal Infections and Treatments | Lifetime | 206 | IT 2 | 98.63 |
| Long-Term Effects of COVID-19 | Lifetime | 445 | IT 75 | 96.61 |
| Sepsis Diagnosis and Treatment | Lifetime | 449 | IT 13 | 98.03 |
| Urinary Tract Infections Management | Lifetime | 353 | IT 6 | 97.63 |
| Infective Endocarditis Diagnosis and Management | Lifetime | 691 | IT 40 | 97.49 |
| Clostridium difficile and Clostridium perfringens research | Lifetime | 694 | IT 23 | 95.49 |
| Neutropenia and Cancer Infections | Lifetime | 553 | IT 37 | 95.51 |
| Infections and bacterial resistance | Lifetime | 564 | IT 26 | 82.55 |
| Antibiotic Resistance in Bacteria | 2021-2025 | 1 | IT 1 | 99.87 |
| Antibiotic Use and Resistance | 2021-2025 | 1 | IT 1 | 99.90 |
| Antibiotics Pharmacokinetics and Efficacy | 2021-2025 | 1 | IT 1 | 99.88 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 4 | IT 1 | 99.73 |
| Pneumocystis jirovecii pneumonia detection and treatment | 2021-2025 | 3 | IT 1 | 99.21 |
| Pneumonia and Respiratory Infections | 2021-2025 | 6 | IT 1 | 99.54 |
| Antifungal resistance and susceptibility | 2021-2025 | 7 | IT 1 | 99.71 |
| Antimicrobial Resistance in Staphylococcus | 2021-2025 | 12 | IT 2 | 98.95 |
| COVID-19 Clinical Research Studies | 2021-2025 | 263 | IT 24 | 98.69 |
| Streptococcal Infections and Treatments | 2021-2025 | 22 | IT 1 | 97.75 |
| Fungal Infections and Studies | 2021-2025 | 30 | IT 1 | 98.91 |
| Nosocomial Infections in ICU | 2021-2025 | 20 | IT 2 | 98.26 |
| Long-Term Effects of COVID-19 | 2021-2025 | 505 | IT 74 | 95.53 |
| Sepsis Diagnosis and Treatment | 2021-2025 | 281 | IT 23 | 95.42 |
| Urinary Tract Infections Management | 2021-2025 | 261 | IT 12 | 89.64 |
| Respiratory Support and Mechanisms | 2021-2025 | 897 | IT 111 | 91.31 |
| Clostridium difficile and Clostridium perfringens research | 2021-2025 | 617 | IT 39 | 83.50 |
| Clinical Reasoning and Diagnostic Skills | 2021-2025 | 858 | IT 15 | 60.80 |
| Thermal Regulation in Medicine | 2021-2025 | 917 | IT 55 | 55.58 |
| Parasitic Diseases Research and Treatment | 2021-2025 | 767 | IT 43 | 52.24 |
| Infections and bacterial resistance | 2021-2025 | 676 | IT 34 | 32.56 |
